MARKET

NMRA

NMRA

Neumora Therapeutics Inc
NASDAQ
1.700
-0.020
-1.16%
After Hours: 1.700 0 0.00% 19:01 06/30 EDT
OPEN
1.710
PREV CLOSE
1.720
HIGH
1.810
LOW
1.650
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
3.650
52 WEEK LOW
0.7158
MARKET CAP
314.98M
P/E (TTM)
-1.2814
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NMRA last week (0622-0626)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS), Neumora Therapeutics, Inc. (NMRA) and Amgen (AMGN)
TipRanks · 06/22 12:23
Weekly Report: what happened at NMRA last week (0615-0619)?
Weekly Report · 06/22 09:26
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 06/19 09:09
Neumora Therapeutics Is Maintained at Outperform by Mizuho
Dow Jones · 06/18 17:53
Neumora Therapeutics Price Target Cut to $4.00/Share From $6.00 by Mizuho
Dow Jones · 06/18 17:53
Mizuho Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $4
Benzinga · 06/18 17:42
Neumora Therapeutics price target lowered to $4 from $6 at Mizuho
TipRanks · 06/18 12:11
More
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Webull offers Neumora Therapeutics Inc stock information, including NASDAQ: NMRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NMRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NMRA stock methods without spending real money on the virtual paper trading platform.